Based on prior published pilot studies, the investigators have initiated a larger, multi-site
placebo-controlled clinical trial with Alzheimer's disease (AD) patients and individuals
diagnosed with Mild Cognitive Impairment (MCI), with the hopes of (1) confirming (or denying)
the above promising clinical findings, and (2) determining whether or not our formulation can
delay MCI "conversion" to AD.